Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial

Eur J Cancer. 2024 Sep:209:114276. doi: 10.1016/j.ejca.2024.114276. Epub 2024 Aug 9.

Abstract

Background: Metastatic Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors characterized by high morbidity and limited systemic treatment options, mainly based on radiometabolic treatments or chemotherapy. Based on the preclinical rationale that PGGLs carcinogenesis relies on angiogenesis, treatment with tyrosine kinase inhibitors (TKI) may represent another viable therapeutic option.

Methods: We conducted a prospective phase II study in patients with metastatic or unresectable PGGLs. Patients received sunitinib (50 mg daily for 4 weeks, followed by a 2-week rest period) until progressive disease (PD), unacceptable toxicity or consent withdrawal. The primary endpoint was 12-month progression-free survival (PFS) rate; secondary endpoints were safety overall response rate (ORR) according to RECIST 1.1 criteria and overall survival (OS). EudraCT Number: 2011-002632-99.

Results: Fifty patients were included. At a median follow-up of 71.7 months (IQR 35.4-100.1), the 1 year-PFS rate was 53.4 % (95 %CI 41.1-69.3) and median PFS was 14.1 months (95 % CI 8.9-25.7). ORR was 15.6 %, the median OS was 49.4 months (95 %CI 21.2-NA), and grade 3 or higher treatment-related adverse events were reported in 34 % patients. No significant correlation was found between specific genetic alterations or genomic clusters and sunitinib efficacy.

Conclusion: Sunitinib is an active drug in patients with advanced PGGLs, capable of inducing prolonged disease control with a manageable toxicity profile.

Keywords: Paraganglioma; Pheocromocytoma; Sunitinib; TKI.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adrenal Gland Neoplasms* / drug therapy
  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Paraganglioma* / drug therapy
  • Paraganglioma* / pathology
  • Pheochromocytoma* / drug therapy
  • Pheochromocytoma* / pathology
  • Progression-Free Survival
  • Prospective Studies
  • Sunitinib* / adverse effects
  • Sunitinib* / therapeutic use

Substances

  • Sunitinib
  • Antineoplastic Agents